Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the present application.

Listing of Claims

1. (currently amended) A compound of formula (I)



(I)

wherein,

Rx is H or C1-C4 alkyl;

Ry is H or C1-C4 alkyl;

each Rz group is independently H or C1-C4 alkyl, with the proviso that not more than 3 Rz groups may be C1-C4 alkyl;

R1 is C1-C6 alkyl (optionally substituted with 1, 2 or 3 halogen atoms and/or with 1 substituent selected from C1-C4 alkylthio (optionally substituted with 1, 2 or 3 fluorine atoms), C1-C4 alkoxy (optionally substituted with 1, 2 or 3 fluorine atoms), C3-C6 cycloalkoxy, C1-C4 alkylsulfonyl, cyano, -CO-O(C1-C2 alkyl), -O-CO-(C1-C2 alkyl) and hydroxy); C2-C6 alkenyl (optionally substituted with 1, 2 or 3 halogen atoms); C3-C6 cycloalkyl (optionally substituted with 1, 2 or 3 halogen atoms and/or with 1 substituent selected from C1-C4 alkoxy and hydroxy) wherein one C-C bond within the cycloalkyl moiety is optionally substituted by an O-C, S-C or C=C bond; C4-C7 cycloalkylalkyl (optionally substituted with 1, 2 or 3 halogen atoms and/or with 1 substituent selected from C1-C4 alkoxy and hydroxy) wherein one C-C bond within the cycloalkyl moiety is optionally substituted by an O-C, S-C or C=C bond; or $(CH_2)_nAr2$ wherein n is 0 or 1; and

Ar1 and Ar2 are each independently a phenyl ring or a 5- or 6-membered heteroaryl ring each of which is optionally substituted with 1, 2 or 3 substituents (depending upon the number of available substitution positions) each independently selected from C1-C4 alkyl (optionally substituted with 1, 2 or 3 halogen atoms), C1-C4 alkoxy (optionally substituted with 1, 2 or 3 halogen atoms), C1-C4 alkylthio (optionally substituted with 1, 2 or 3 halogen atoms), -CO-O(C1-C4 alkyl), cyano, -NRR, -CONRR, halo and hydroxy and/or with 1 substituent selected

from pyridyl, thiophenyl, phenyl, benzyl and phenoxy each of which is optionally ring-substituted with 1, 2 or 3 substituents each independently selected from halogen, C1-C4 alkyl ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~, C1-C4 alkoxy ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~, carboxy, nitro, hydroxy, cyano, -NRR, -CONRR, SO_2NRR and SO_2R); and

each R is independently H or C1-C4 alkyl;

or a pharmaceutically acceptable salt thereof.

2. (currently amended): A compound according to claim 1, having the configuration of formula (II)



(II)

wherein, Rx, Ry, Rz, R1 and Ar1 are as defined in claim 1;

or a pharmaceutically acceptable salt thereof.

3. (currently amended): A compound according to ~~any preceding~~ claim 1, wherein Rx is H.

4. (currently amended): A compound according to ~~any preceding~~ claim 1, wherein Ry is H.

5. (currently amended): A compound according to ~~any preceding~~ claim 1, wherein Rz is H.

6. (currently amended): A compound according to claim 1 of formula (III)



(III)

wherein, R1 and Ar1 are as defined in claim 1; or a pharmaceutically acceptable salt thereof.

7. (currently amended): A compound according to claim 6 of formula (IV)



(IV)

wherein,

R1 is $(CH_2)_n$Ar2 wherein n is 0 or 1 and Ar2 is a phenyl ring or a pyridyl ~~(preferably 2-pyridyl)~~ ring each of which may be substituted with 1, 2 or 3 substituents each independently selected from C1-C4 alkyl ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~, C1-C4 alkoxy ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~, C1-C4 alkylthio ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~, halo and hydroxy;

A is N or CR6 ~~(preferably CR6)~~; R2 is C1-C4 alkyl ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~, C1-C4 alkoxy ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~, C1-C4 alkylthio ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~, halo, hydroxy, pyridyl, thiophenyl, phenyl ~~(~~optionally substituted with 1, 2 or 3 substituents each independently selected from halogen, C1-C4 alkyl ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~, or C1-C4 alkoxy ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~,))~~ or phenoxy ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~; R3 is H; R4 is H; R5 is H, C1-C4 alkyl ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~, C1-C4 alkoxy ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~, C1-C4 alkylthio ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~, halo or hydroxy; and R6~~, (~~if present~~,)~~ is H; or a pharmaceutically acceptable salt thereof.

8. (currently amended): A compound according to claim 7 of formula (V)



(V)

wherein,

R1 is $(CH_2)_nAr2$ wherein n is 0 and Ar2 is a phenyl ring optionally substituted with 1 or 2 substituents each independently selected from C1-C4 alkyl ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~, C1-C4 alkoxy ~~(~~optionally substituted with 1, 2 or 3 halogen atoms~~)~~, halo and hydroxy;

R2 is C1-C4 alkyl ~~(~~optionally substituted with 1, 2 or 3 fluorine atoms~~)~~, C1-C4 alkoxy ~~(~~optionally substituted with 1, 2 or 3 fluorine atoms~~)~~, phenyl ~~(~~optionally substituted with 1, 2 or 3 substituents each independently selected from fluorine and trifluoromethoxy~~)~~, pyridyl ~~(preferably 3-pyridyl)~~ or phenoxy; and

R5 is H or F;

or a pharmaceutically acceptable salt thereof.

9. (currently amended): A compound <u>according to claim 8</u> of formula (VI)



(VI)

wherein,

R2 is C1-C4 alkyl ~~(~~optionally substituted with 1, 2 or 3 fluorine atoms~~)~~, C1-C4 alkoxy ~~(~~optionally substituted with 1, 2 or 3 fluorine atoms~~)~~, phenyl ~~(~~optionally substituted with 1, 2 or 3 substituents each independently selected from fluorine and trifluoromethoxy~~)~~, pyridyl ~~(preferably 3-pyridyl)~~ or phenoxy; and

R5 is H or F;

or a pharmaceutically acceptable salt thereof.

10. (currently amended): A pharmaceutical composition comprising a compound as claimed in ~~any one of claims 1 to 9~~ claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent, excipient or carrier

11. (cancelled)

12. (cancelled)

13. (cancelled)

14. (cancelled)

15. (cancelled)

16. (currently amended): A method for treating ~~disorders associated with norepinephrine dysfunction~~ attention-deficit/hyperactivity disorder, a cognitive disorder, conduct disorder, oppositional defiant disorder, depression, hot flashes, or vasomotor symptoms in mammals comprising administering to a patient in need thereof an effective amount of a compound as claimed in ~~any one of claims 1 to 9~~ claim 1, or a pharmaceutically acceptable salt thereof.